Compare CRSP & MMYT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRSP | MMYT |
|---|---|---|
| Founded | 2013 | 2000 |
| Country | Switzerland | India |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Transportation Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 5.3B |
| IPO Year | 2016 | 2010 |
| Metric | CRSP | MMYT |
|---|---|---|
| Price | $46.38 | $39.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 3 |
| Target Price | $70.29 | ★ $106.33 |
| AVG Volume (30 Days) | ★ 2.0M | 1.3M |
| Earning Date | 05-05-2026 | 01-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $289,590,000.00 | N/A |
| Revenue This Year | $1,082.59 | $17.65 |
| Revenue Next Year | $87.74 | $17.72 |
| P/E Ratio | ★ N/A | $107.67 |
| Revenue Growth | ★ 9169.85 | N/A |
| 52 Week Low | $30.06 | $39.42 |
| 52 Week High | $78.48 | $113.85 |
| Indicator | CRSP | MMYT |
|---|---|---|
| Relative Strength Index (RSI) | 38.40 | 23.16 |
| Support Level | N/A | N/A |
| Resistance Level | $60.63 | $103.73 |
| Average True Range (ATR) | 2.30 | 2.32 |
| MACD | -0.84 | -0.41 |
| Stochastic Oscillator | 10.22 | 6.91 |
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
MakeMyTrip Ltd is an online travel company, which provides online booking solutions for day-to-day travel needs. The company's operating segment includes Air ticketing; Hotels and packages; Bus ticketing and Others. It generates maximum revenue from the Hotels and packages segment. The Hotels and packages segments include internet-based platforms, call-centers, and branch offices, which provide holiday packages and hotel reservations. Its Air ticketing segment includes internet-based platforms, provides the facility to book domestic and international air tickets. Geographically, it derives a majority of revenue from India and also has a presence in the United States; South East Asia; Europe, and other countries.